CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

CDMO Subsection

Insights into the latest developments in CDMO services and manufacturing.

Continue reading

Injectables Subsection

Expert perspectives on the evolving needs of injectable therapies and packaging.

Continue reading

Nasal & Pulmonary Subsection

Exploring the latest developments in inhalation technologies, respiratory delivery and sustainability

Continue reading

Advertisement

CPHI Milan
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Lifecore Biomedical

Advertisement

Solstice

Isolators in Aseptic Production and their Requirements for Highly Active Substances

The new EMA (European Medicine Agency) Draft Guide of Annex 1 has drawn a lot of attention to isolators. In the paper, the employee in aseptic production is seen as the greatest risk factor for product contamination, and Richard Denk at SKAN AG demonstrates how contamination is particularly prevalent in areas that handle product in open containers; e.g., when filling pharmaceuticals into vials and syringes they should be protected with suitable barrier systems, such as isolators.

[gview file=”https://www.ipimediaworld.com/wp-content/uploads/2019/10/Isolators-in-Aseptic-Production-and-their.pdf”]

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Tjoapack
Aptar – 08/01/2026